Aitiologic
A precision medicine startup providing multi-modal liquid biopsy solutions for early disease detection and targeted therapy.
Website: https://www.aitiologic.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | Aitiologic |
| Tagline | A precision medicine startup providing multi-modal liquid biopsy solutions for early disease detection and targeted therapy. [aitiologic.com, retrieved 2024] |
| Headquarters | Vienna, Austria [Crunchbase] |
| Founded | 2023 [Crunchbase] |
| Stage | Seed [Crunchbase] |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2): Dr. Andreas E. Posch and Stephan Beisken [Deutsche Startups, September 2026] |
| Funding Label | Seed |
| Total Disclosed | ~$9,600,000 [Brutkasten, October 2024] [Deutsche Startups, September 2026] |
Links
Open sources
- Website: https://www.aitiologic.com/
- Product: https://www.aitiologic.com/platform/platform
What an Investor Needs First
PUBLIC Aitiologic is building AI-assisted, tissue-resolved liquid-biopsy diagnostics, with an initial focus on first-trimester preeclampsia risk assessment, and it merits investor attention now because the company has moved from early stealth financing into a larger seed round tied to a clearly defined lead program [aitiologic.com, retrieved 2024] [Brutkasten, October 2024] [Brandl Talos, September 2026]. Founded in Vienna in 2023, the company emerged publicly in 2024 with more than €2.5 million in funding and grants, then announced a further €6.4 million seed financing in September 2026, which indicates continued investor support even as the clinical and commercial path remains early [Brutkasten, October 2024] [Deutsche Startups, September 2026] [GlobeNewswire, September 2026].
The core product claim is the Aitios® platform, which analyzes circulating cell-free DNA through genomic, epigenomic, and fragmentomic signals to infer tissue of origin and disease-related biological changes; in plain terms, the company is trying to make liquid biopsy more clinically specific than a broad cfDNA readout alone [aitiologic.com, retrieved 2024] [aitiologic.com, retrieved 2026]. Earlier public materials pointed to non-invasive prenatal testing and oncology applications, but current messaging is narrower around maternal health, which is often a healthier sign of focus at seed stage than an overly wide platform story [viennabiocenter.org] [aitiologic.com, retrieved 2024].
The founding team appears well matched to the technical thesis on paper. Andreas Posch is identified as founder and CEO, and multiple public sources state that Aitiologic builds on tissue-specific liquid-biopsy intellectual property he co-invented at Siemens Healthineers; Stephan Beisken is identified as co-founder and CTO [startup.eu, September 2026] [Andreas Posch - LinkedIn, retrieved 2026] [LinkedIn, retrieved 2026]. The September 2026 financing also brought in Gordon Sanghera, Oxford Nanopore's co-founder and former CEO, as an investor and advisory-board member, which does not validate product performance but does strengthen the scientific and strategic signal around the company [Brandl Talos, September 2026].
Commercially, the company is best understood today as a B2B diagnostics platform bet rather than a scaled operating business. Public materials support the funding base and the technical ambition, but they do not yet establish named customers, clinical-lab deployments, or revenue traction, so the next 12 to 18 months likely turn on translational proof: whether the preeclampsia program generates credible validation data, whether the platform can show differentiated tissue-resolution in real workflows, and whether that translates into lab, provider, or industry partnerships [aitiologic.com, retrieved 2024] [GenomeWeb] [Deutsche Startups, September 2026].
Claim stands unchecked -- This section relies materially on company statements for product scope and differentiation, with partial corroboration on team and financing from Brutkasten, Deutsche Startups, Brandl Talos, LinkedIn, and Startup.eu.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed ~$9,600,000 |
Inside the Company
PUBLIC
Aitiologic entered the public record in stages rather than with a long operating history. The company describes itself as a precision medicine startup focused on multi-modal liquid biopsy for early disease detection and targeted therapy, and public company profiles place it in Vienna, Austria, with a 2023 founding date [aitiologic.com, retrieved 2024] [Crunchbase].
The early milestones that can be supported from the permitted sources are limited but directionally clear. Crunchbase lists Aitiologic as a seed-stage company, while the company website centers the Aitios® platform and presents first-trimester preeclampsia risk assessment as the initial disclosed program, indicating that maternal-fetal health is the first visible wedge rather than a broad launch across all liquid-biopsy use cases [Crunchbase] [aitiologic.com, retrieved 2024]. Public materials reviewed for this section do not establish a legal entity name beyond the operating brand, so the chronology is best read as 2023 formation followed by product positioning that was public by 2024 [Crunchbase] [aitiologic.com, retrieved 2024].
Partially corroborated -- Based on company website disclosures and Crunchbase profile data, with limited independent confirmation inside this section.
Under the Hood
Reported and inferred Aitiologic is making a relatively specific technical claim for a young diagnostics company: that its core platform can read more than the presence of circulating cell-free DNA and instead infer tissue context from multiple signal layers [aitiologic.com, retrieved 2024]. On the company’s website, the Aitios® platform is described as a tissue-resolved liquid-biopsy system that analyzes genomic, epigenomic, and fragmentomic features in cfDNA to identify tissue of origin and disease-associated biological change [aitiologic.com, retrieved 2024]. That matters because the product story is not framed as a general AI tool for healthcare workflows, but as an assay-and-interpretation stack aimed at earlier detection and more precise patient stratification in molecular diagnostics [aitiologic.com, retrieved 2024] [GenomeWeb].
The lead disclosed application is narrower than the platform language suggests, which is usually the more useful signal. Aitiologic says its initial program is first-trimester preeclampsia risk assessment, and its materials also describe an Aitios® NIPPT application for non-invasive prenatal and preeclampsia testing in early pregnancy [aitiologic.com, retrieved 2024] [aitiologic.com, retrieved 2026]. Earlier public materials connected the underlying technology to non-invasive prenatal testing and oncology, and linked it to patented liquid-biopsy work co-invented by founder Andreas Posch at Siemens Healthineers [viennabiocenter.org] [startup.eu, September 2026]. The technical proposition is interesting, but most operating detail remains company-described: no verified clinical performance metrics, regulatory milestones, named deployments, or external validation studies were supplied in the materials reviewed [aitiologic.com, retrieved 2024] [GlobeNewswire, September 2026].
A small hiring signal points to the practical work required to turn the platform into a clinical product. The company has publicly listed a "(Junior) Assay Development Scientist (NGS)" role, which supports the view that next-generation sequencing sits close to the current productization effort, though any deeper stack description would be speculative and should be treated only as process inference rather than confirmed architecture [aitiologic.com, retrieved 2024]. For now, the public record supports a credible platform concept and a defined prenatal wedge, while leaving the key diligence questions where they usually sit in diagnostics: assay performance, reproducibility, clinical utility, and the path from promising signal biology to adopted test volume [GenomeWeb] [Brutkasten, October 2024].
Claim stands unchecked -- This section relies materially on company website and company-linked product descriptions, with limited independent corroboration from GenomeWeb, Brutkasten, and Vienna BioCenter on the broad platform framing.
Market Research
PUBLIC This market matters now because Aitiologic sits at the intersection of two areas drawing sustained clinical and investor attention, liquid biopsy and maternal-fetal risk assessment, but the public record still says more about category momentum than about the company's addressable market in hard numbers [GenomeWeb] [GlobeNewswire, September 2026].
The available sources do not provide a cited TAM, SAM, or SOM for Aitiologic itself, so the cleaner approach is to anchor on adjacent markets rather than force precision that the evidence does not support. Public materials consistently place the company in liquid biopsy, with an initial program in first-trimester preeclampsia risk assessment and earlier references to non-invasive prenatal testing and oncology applications [aitiologic.com, retrieved 2024] [viennabiocenter.org]. That means the relevant demand pool is not a single market, but an overlap between cfDNA-based diagnostics, prenatal screening workflows, and, over time, oncology diagnostics if the platform extends as described by the company [aitiologic.com, retrieved 2024].
The strongest tailwind is clinical interest in earlier, less invasive detection using blood-based assays. Aitiologic's disclosed approach analyzes circulating cell-free DNA with genomic, epigenomic, and fragmentomic signals to infer tissue of origin and disease-associated biological change, which aligns with a broader diagnostic shift toward multi-signal liquid biopsy rather than single-marker testing [aitiologic.com, retrieved 2024] [GenomeWeb]. In maternal health, the appeal is straightforward: first-trimester risk stratification could fit an existing prenatal care pathway if clinical validity and workflow economics hold up, and it targets a condition where earlier signal detection is materially more useful than retrospective diagnosis [aitiologic.com, retrieved 2024] [GlobeNewswire, September 2026].
The substitute and adjacent markets are also clear from the source trail. Earlier Vienna BioCenter materials linked the platform to non-invasive prenatal testing and oncology, which suggests Aitiologic is pursuing a technology platform thesis rather than a single-assay company from day one [viennabiocenter.org]. That broadens the strategic market lens, but it also raises the bar: in prenatal screening the company will be compared with established testing pathways, while in oncology any eventual expansion would place it near a crowded field of liquid-biopsy developers and laboratory-developed test incumbents, even if no direct named competitors were confirmed in the supplied research [GenomeWeb] [viennabiocenter.org].
Regulation and reimbursement are likely to shape market timing as much as technical performance. For any blood-based diagnostic, especially one touching prenatal care, evidence generation, regulatory pathway design, and payer acceptance can determine whether a clinically interesting assay becomes a routine test or remains a niche specialty offering. The 2026 financing announcement frames proceeds around advancing the platform and the preeclampsia lead program, which implies that market formation is still tied to clinical development milestones rather than to a documented scaled commercial rollout [GlobeNewswire, September 2026] [Brandl Talos, September 2026].
| Market lens | Public evidence | Relevance to Aitiologic |
|---|---|---|
| Liquid biopsy | Aitiologic is described as developing tissue-resolved liquid biopsy diagnostics using cfDNA signals [GenomeWeb] [aitiologic.com, retrieved 2024] | Core category anchor for the platform |
| Maternal-fetal diagnostics | The initial disclosed program is first-trimester preeclampsia risk assessment [aitiologic.com, retrieved 2024] [GlobeNewswire, September 2026] | Near-term clinical wedge |
| Prenatal screening | Earlier company materials referenced non-invasive prenatal testing [viennabiocenter.org] | Adjacent workflow and buyer context |
| Oncology diagnostics | Earlier materials also referenced oncology applications [viennabiocenter.org] | Longer-term expansion path if validated |
The table shows why market framing is more important than market sizing at this stage. Public evidence supports the category map, but not a quantified bottom-up revenue opportunity, so any sizing claim would still need third-party market data or management guidance before it becomes decision-useful.
Partially corroborated -- Section relies on company materials and one independent trade publication for category definition, with no confirmed third-party TAM/SAM/SOM data in the supplied sources.
Competition and Substitutes
Positioning
MIXED Aitiologic is positioning itself against established liquid-biopsy and molecular-diagnostics workflows by arguing that tissue-resolved interpretation of cell-free DNA can improve early detection and patient stratification in narrower clinical use cases before it tries to compete across broader oncology or prenatal testing markets [aitiologic.com, retrieved 2024] [GenomeWeb].
The immediate competitive map is easier to understand by segment than by a single peer set. In maternal-fetal health, the practical alternatives are existing prenatal screening and risk-assessment workflows rather than a like-for-like tissue-resolved cfDNA product, because the company's lead disclosed program is first-trimester preeclampsia risk assessment rather than a general oncology assay [aitiologic.com, retrieved 2024] [GlobeNewswire, September 2026]. In oncology and broader liquid biopsy, the pressure comes from better-capitalized incumbents and specialist assay developers already associated with cfDNA testing, while adjacent substitutes include standard laboratory diagnostics and imaging pathways that are already embedded in care delivery [GenomeWeb] [viennabiocenter.org].
That distinction matters because Aitiologic's strongest public edge today appears to be technical positioning rather than distribution. The company says its Aitios® platform combines genomic, epigenomic, and fragmentomic signals to infer tissue of origin and related biological changes from circulating cell-free DNA, and public materials tie that platform to intellectual property co-invented by founder and CEO Dr. Andreas E. Posch at Siemens Healthineers and exclusively licensed to the company [aitiologic.com, retrieved 2024] [startup.eu, September 2026]. If that IP position translates into clinically differentiated assay performance, it could be durable; if differentiation rests mainly on platform claims without published clinical validation or commercial adoption, the edge is more perishable because better-funded diagnostics groups can approach the same customer budget from stronger installed bases [GenomeWeb] [Brutkasten, October 2024].
The exposure is also fairly clear in public evidence. Aitiologic has disclosed no named commercial customers, lab deployments, or hospital contracts in the materials reviewed, which leaves it vulnerable to competitors that already control clinical-lab channels, reimbursement know-how, or physician relationships [GenomeWeb] [aitiologic.com, retrieved 2024]. Oxford Nanopore co-founder Gordon Sanghera joining as an investor and advisory-board member adds technical and category credibility, but advisory support is not the same thing as owned distribution, and the company remains at seed stage while pursuing a clinically sensitive indication that will likely demand validation, regulatory execution, and capital discipline [Brandl Talos, September 2026] [Deutsche Startups, September 2026].
The most plausible 18-month scenario is a narrower one than the category narrative might suggest. Aitiologic is the winner if tissue-resolved performance in preeclampsia or adjacent pregnancy-related conditions shows enough clinical signal to earn early laboratory or strategic-partner interest, because that would give the company a defendable wedge before it expands back toward oncology or broader prenatal applications [aitiologic.com, retrieved 2026] [GlobeNewswire, September 2026]. The loser if commercialization outruns validation is the generic liquid-biopsy challenger cohort rather than a named direct peer in the sourced record, since larger diagnostics incumbents and established testing workflows can simply wait while seed-stage entrants absorb the cost of proving clinical utility [GenomeWeb] [viennabiocenter.org].
Opportunity
PUBLIC
The prize here is unusually large for a company this early, because a tissue-resolved liquid biopsy platform that works first in pregnancy and then extends into broader disease detection could sit at the junction of diagnostics, clinical decision support, and biopharma stratification across multiple high-value care settings [aitiologic.com, retrieved 2024] [GlobeNewswire, September 2026].
The headline opportunity is not simply to launch a single maternal-health assay. It is to become a platform supplier for tissue-of-origin interpretation in cell-free DNA, with preeclampsia as the first commercial wedge and oncology or other disease areas as later extensions [aitiologic.com, retrieved 2024] [viennabiocenter.org] [GlobeNewswire, September 2026]. That outcome is reachable, rather than purely aspirational, because the company has disclosed a specific initial program in first-trimester preeclampsia risk assessment, has tied the platform to patented technology co-invented by founder and CEO Andreas Posch at Siemens Healthineers, and has attracted a 2026 seed round that included Heal Capital, Ananda Impact Ventures, and Oxford Nanopore co-founder Gordon Sanghera as investor and advisory-board member [aitiologic.com, retrieved 2024] [startup.eu, September 2026] [Brandl Talos, September 2026]. In practical terms, the upside case is that Aitiologic becomes valuable not only for one test, but for the interpretive layer that lets cfDNA assays say more about tissue origin and disease biology.
That can scale along a few distinct paths, and the sources support more than one of them.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Maternal-health wedge becomes a clinical beachhead | Aitiologic gains early adoption around first-trimester preeclampsia risk assessment, then extends into adjacent pregnancy-related conditions such as gestational diabetes | Clinical validation or commercial uptake of the disclosed preeclampsia lead program | The company has publicly identified first-trimester preeclampsia as its lead program and has said the platform is designed to expand into other pregnancy-related conditions [aitiologic.com, retrieved 2024] [GlobeNewswire, September 2026] |
| Platform supplier to diagnostics and labs | The company licenses or embeds Aitios® into third-party testing workflows, becoming a tissue-resolution layer for existing liquid-biopsy infrastructure | A partnership with diagnostic labs or test developers that need improved tissue-of-origin interpretation | Aitiologic describes Aitios® as a foundational multi-modal liquid biopsy platform for tissue-resolved cfDNA signal interpretation, which lends itself to platform positioning beyond a single branded assay [aitiologic.com, retrieved 2026] [GenomeWeb] |
| Cross-over into oncology stratification | Aitiologic uses data, assay, and interpretation capabilities built in maternal-fetal health to move into oncology applications where tissue-of-origin calls are commercially valuable | Publication of oncology-focused validation data or a biopharma collaboration | Earlier company materials referenced oncology applications, and September 2026 financing was framed around advancing the tissue-resolved liquid biopsy platform rather than only one prenatal test [viennabiocenter.org] [GlobeNewswire, September 2026] |
The compounding mechanism, if this works, is a data and workflow flywheel. Each validated use case can add more labeled cfDNA signal across genomic, epigenomic, and fragmentomic layers, which in turn can improve interpretation accuracy for adjacent assays and make the platform more useful to labs, providers, and possibly biopharma users seeking patient stratification [aitiologic.com, retrieved 2024] [GenomeWeb]. There is also a licensing component to the moat if the Siemens-originated intellectual property remains central to tissue-specific signal interpretation and is exclusively licensed to the company, because that can make Aitiologic more than a services business and less dependent on a single diagnostic SKU [startup.eu, September 2026]. The 2026 financing matters in this context because it was raised specifically to advance both the platform and the preeclampsia program, suggesting investors are backing the repeatability of the underlying engine, not only the first assay [GlobeNewswire, September 2026] [Brandl Talos, September 2026].
The size of the win is best framed conditionally, because no credible public market or TAM figure was provided in the source set. If the strongest scenario is the second one, where Aitiologic becomes an embedded interpretation layer for multiple liquid-biopsy workflows, the company could resemble a strategic diagnostics platform asset rather than a single-product maternal-health company, especially given the involvement of diagnostics-focused backers and advisers such as Heal Capital and Gordon Sanghera [Brandl Talos, September 2026] [Deutsche Startups, September 2026]. In that case, the upside could be venture-scale and platform-like in strategic value, with worth driven by assay breadth, clinical validation, and partner integration depth rather than by one test alone (scenario, not a forecast). The available evidence does not support a tighter valuation range, but it does support the more important point: Aitiologic is trying to own an interpretive layer in liquid biopsy, and that is a meaningfully larger outcome than shipping a niche prenatal assay [aitiologic.com, retrieved 2026] [GlobeNewswire, September 2026].
Partially corroborated -- This section relies on a mix of company disclosures and partially corroborating publisher coverage, with no independent public market-sizing source or named customer evidence in the source set.
Sources
Open sources
[aitiologic.com, retrieved 2024] aitiologic | Liquid Biopsy for Precision Medicine | https://www.aitiologic.com/
[Crunchbase] Aitiologic | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/aitiologic
[Deutsche Startups, September 2026] syte erhält 9 Millionen - aitiologic sammelt 6,4 Millionen ein - Ferm Labs erhält 3 Millionen | https://www.deutsche-startups.de/2026/09/17/syte-erhaelt-9-millionen-aitiologic-sammelt-64-millionen-ein-fer-labs-erhaelt-3-millionen/
[Brutkasten, October 2024] Aitiologic: Wiener Diagnostik-Startup verlässt mit 2,5 Mio. Euro-Finanzierung ‘Stealth Mode’ | https://brutkasten.com/artikel/aitiologic-finanzierung
[Brandl Talos, September 2026] BRANDL TALOS advises Aitiologic on EUR 6.4 million seed financing round | https://brandltalos.com/en/insight/brandl-talos-advises-aitiologic-on-eur-6-4-million-seed-financing-round/
[GlobeNewswire, September 2026] Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program | https://www.globenewswire.com/news-release/2026/09/15/3361783/0/en/aitiologic-raises-6-4-million-in-oversubscribed-seed-financing-to-advance-tissue-resolved-liquid-biopsy-platform-and-preeclampsia-lead-program.html
[viennabiocenter.org] Aitiologic Emerges from Stealth Mode | https://www.viennabiocenter.org/about/news/aitiologic-emerges-from-stealth-mode/
[startup.eu, September 2026] Aitiologic €6.4 M Seed | https://www.startup.eu/investments/aitiologic-6-4-m-seed-09-2026
[Andreas Posch - LinkedIn, retrieved 2026] Andreas Posch | LinkedIn | https://me.sh/profile/andreas-posch
[LinkedIn, retrieved 2026] Stephan Beisken - Co-Founder & CTO at Aitiologic | https://at.linkedin.com/in/stephanbeisken
[aitiologic.com, retrieved 2026] Aitios® Platform | aitiologic | https://www.aitiologic.com/platform/platform
[GenomeWeb] Aitiologic Developing Liquid Biopsy Assay for Tissue-of-Origin Analysis, Early Disease Detection | GenomeWeb | https://www.genomeweb.com/liquid-biopsy/aitiologic-developing-liquid-biopsy-assay-tissue-origin-analysis-early-disease
Articles about Aitiologic
- Aitiologic's Liquid Biopsy Platform Takes Aim at Preeclampsia — The Vienna-based startup's €6.4 million seed round will advance its AI-powered Aitios platform, starting with a high-stakes test for a dangerous pregnancy complication.